Skip to main content
Fig. 6 | Clinical Epigenetics

Fig. 6

From: Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells

Fig. 6

Expression changes and anti-VEGF/VEGFR drug efficacies following knockdown of FLT1 or KDR in vitro. Expression of FLT1 (a) and KDR (b) in SNU482 renal cancer cells after transduction with an shRNA targeting FLT1 or KDR. The effects of bevacizumab, an anti-FLT1 peptide, an anti-KDR antibody, sunitinib, and axitinib on proliferation were evaluated in SNU482 cells transduced with lentiviral vectors expressing FLT1 or KDR or an empty lentiviral vector (c). The error bars show the standard errors

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us